VRTX
Vertex Pharmaceuticals Incorporated
Cash flow statement
| USDLine, in USD | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.69B | 3.63B | −0.49B | 3.54B | 4.13B | 2.64B | 3.25B | 1.57B | 1.27B | 0.84B | 0.24B | −0.37B | −0.57B | −61M | 0.27B | 0.14B | −0.64B | −0.43B | −0.23B |
| 492M | 438M | 298M | 200M | 205M | 235M | 260M | 75M | 95M | 99M | 57M | 45M | 51M | 51M | 71M | 35M | 38M | 23M | 32M | |
| Free cash flow | 3.20B | 3.19B | −0.79B | 3.34B | 3.93B | 2.41B | 2.99B | 1.49B | 1.17B | 0.75B | 0.18B | −0.41B | −0.62B | −0.11B | 0.20B | 0.11B | −0.67B | −0.45B | −0.26B |
| Depreciation and amortization | 237M | 210M | 207M | 181M | 148M | 126M | 110M | 107M | 72M | 61M | 61M | 62M | 63M | 48M | 38M | 35M | 30M | 30M | 32M |
| Stock-based compensation | 669M | 686M | 699M | 581M | 491M | 441M | 430M | 361M | 325M | 293M | 241M | 231M | 178M | 127M | 114M | 118M | 91M | 87M | 58M |
| Buybacks | 1.06B | 2.02B | 1.18B | 0.43B | 0 | 1.43B | 0.54B | 0.19B | 0.35B | 0 | 0 | — | — | — | — | — | — | — | — |
| Free cash flow margin | 24.7% | 26.6% | −7.2% | 33.8% | 44.0% | 31.8% | 48.2% | 35.9% | 38.5% | 30.0% | 10.5% | −39.8% | −107.6% | −9.2% | 12.9% | 7.7% | −469.8% | −442.7% | −147.4% |